(1-Methyl-1H-benzo[d]imidazol-5-yl)methanol, 95.0%, 5g

2-Azabicyclo[2.1.1]hexane-2-sulfonyl chloride, 97%, 500mg

4-(Methylthio)benzenesulfonamide, 25g

1-ethyl-1,4-diazepane dihydrochloride, 95.0%, 1g

3-Bromo-4-trifluoromethylanisole, 95.0%, 10g

Methyl 6-oxo-1,6-dihydropyridine-2-carboxylate, 95.0%, 1g

1-Ethyl-3-methyl-1H-pyrazol-4-ylamine, 95.0%, 500mg

(2,3-Difluoro-5-nitrophenyl)boronic acid, 95.0%, 5g

N-[4-Cyano-3-(trifluoromethyl)phenyl]-2-methacrylamide, 95.0%, 25g

3-Fluoro-4-methoxybenzenesulfonyl chloride, 98.0%, 10g

(1R)-1-(3-Fluoro-4-methylphenyl)ethan-1-amine hydrochloride, 95.0%, 250mg

(4-Bromo-3-methylphenyl)boronic acid, 95.0%, 5g

Plan PLPH S100x/1.25 phase contrast objective